Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage II Bladder Urothelial Carcinoma Clear all
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer
Interventions
SUTENT, Placebo
Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced May 21, 2026, 10:15 PM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Bladder Cancer, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions
3D conformal radiation therapy
Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Bladder Cancer
Interventions
Pembrolizumab, Cryoablation, Avelumab
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced May 21, 2026, 10:15 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Nivolumab in combination with Urelumab, Nivolumab monotherapy
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced May 21, 2026, 10:15 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Interventions
BT5528, Nivolumab
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Encinitas, California • Orange, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced May 21, 2026, 10:15 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
Interventions
Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy
Other · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Carcinoma, Transitional Cell
Interventions
Atezolizumab
Drug
Lead sponsor
Lawrence Fong
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced May 21, 2026, 10:15 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan
Procedure · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Carcinoma, Metastasis
Interventions
Vinflunine, Gemcitabine, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
64
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, docetaxel, gemcitabine hydrochloride, methotrexate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
4
States / cities
Chicago, Illinois • Peoria, Illinois • Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder, Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Metastatic Bladder Cancer
Interventions
durvalumab and tremelimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gemcitabine hydrochloride, pemetrexed disodium
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
121
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 88 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
chemotherapy, tipifarnib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
San Francisco, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Gemcitabine and Cisplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
9
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced May 21, 2026, 10:15 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage I Prostate Cancer, Stage I Renal Cell Cancer, Stage II Bladder Urothelial Carcinoma, Stage II Renal Cell Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage III Renal Cell Cancer
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Radical Cystectomy, Recombinant EphB4-HSA Fusion Protein, Therapeutic Conventional Surgery
Other · Procedure · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced May 21, 2026, 10:15 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Bladder Cancer
Interventions
therapeutic conventional surgery, therapeutic standard lymphadenectomy, therapeutic extended lymphadenectomy
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
29
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
Interventions
Atezolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
269
States / cities
Daphne, Alabama • Mobile, Alabama • Scottsdale, Arizona + 201 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced May 21, 2026, 10:15 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder, Squamous Cell Carcinoma of the Urinary Tract, Primary Adenocarcinoma of the Bladder, Primary Adenocarcinoma of the Urinary Tract, Renal Medullary Carcinoma, Squamous Cell Carcinoma of the Penis
Interventions
Sacituzumab govitecan, Atezolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Stage IV Urethral Cancer, Transitional Cell Carcinoma of the Bladder, Ureter Cancer
Interventions
bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Placebo, Pembrolizumab
Other · Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
28
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Transitional Cell Cancer of the Urothelial Tract
Interventions
Docetaxel, Oxaliplatin
Drug
Lead sponsor
Leonard Appleman
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced May 21, 2026, 10:15 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Sapanisertib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
20
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 10:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Lenalidomide
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Bethesda, Maryland • New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced May 21, 2026, 10:15 PM EDT